{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:45:39Z","timestamp":1790109939109,"version":"4.0.1"},"reference-count":84,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"La Fondation Foch"},{"name":"SIRIC CARPEM"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Dopamine agonists and somatostatin analogs are commonly used in prolactinomas and somatotropinomas. Response to these therapies is heterogeneous. Whether resistance is linked to specific tumor subtypes or to shared mechanisms of resistance is not known. The aim was to explore distinct molecular subtypes of prolactinomas and somatotropinomas and their association with response to treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The transcriptome of 46 prolactinomas and 58 somatotropinomas was analyzed. Unsupervised classifications were generated and tested for association with histological and clinical data, including response to treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four subtypes of prolactinomas were identified, with variable sensitivity to dopamine agonists (P &amp;lt; 10\u22124). Sensitive tumors accumulated in the subgroup with the highest DRD2 expression, while resistant tumors accumulated in the 3 remaining ones, enriched in genes related to cAMP metabolism, to mitochondrial and ribosomal activity, and to immunity, respectively. Sparsely granulated somatotropinomas (N = 16) presented a separated molecular entity, mixing tumors resistant and sensitive to somatostatin analogs. The remaining somatotropinomas were classified into 5 subtypes, with variable sensitivity to somatostatin analogs (P &amp;lt; 10\u22124). Sensitive tumors accumulated in 3 subgroups, characterized by GNAS somatic mutation, PIT1 and SF1 coexpression, and the stem-cell marker SOX2 expression, respectively. Resistant tumors accumulated in the 2 remaining ones, enriched in genes related to cell cycle and to mesenchymal differentiation, respectively. Somatostatin receptor 2 (SSTR2) expression was associated with response to somatostatin analogs in sparsely granulated somatotropinomas (P = .022), but not in other somatotropinomas (P = .923).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Prolactinomas and somatotropinomas were classified into distinct transcriptomic groups. Resistance to medical therapies was linked to distinct tumor subtypes, suggesting distinct mechanisms of resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejendo\/lvaf196","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:30:53Z","timestamp":1761222653000},"page":"474-486","source":"Crossref","is-referenced-by-count":2,"title":["Transcriptomic classification of prolactinomas and somatotropinomas identifies subtypes with variable resistance to treatment"],"prefix":"10.1093","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7550-7023","authenticated-orcid":false,"given":"Fabio","family":"Bioletto","sequence":"first","affiliation":[{"name":"CNRS UMR8104, INSERM U1016, Institut Cochin, Universit\u00e9 Paris Cit\u00e9 , Paris 75014 ,","place":["France"]},{"name":"Division of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin , Turin 10126 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrine","family":"Benanteur","sequence":"additional","affiliation":[{"name":"CNRS UMR8104, INSERM U1016, Institut Cochin, Universit\u00e9 Paris Cit\u00e9 , Paris 75014 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8100-8394","authenticated-orcid":false,"given":"Maria Francesca","family":"Birtolo","sequence":"additional","affiliation":[{"name":"CNRS UMR8104, INSERM U1016, Institut Cochin, Universit\u00e9 Paris Cit\u00e9 , Paris 75014 ,","place":["France"]},{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele Milan 20090 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Gravrand","sequence":"additional","affiliation":[{"name":"CNRS UMR8104, INSERM U1016, Institut Cochin, Universit\u00e9 Paris Cit\u00e9 , Paris 75014 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoann","family":"Martin","sequence":"additional","affiliation":[{"name":"CNRS UMR8104, INSERM U1016, Institut Cochin, Universit\u00e9 Paris Cit\u00e9 , Paris 75014 ,","place":["France"]},{"name":"INSERM U1016, Institut Cochin, Plate-Forme S\u00e9quen\u00e7age et G\u00e9nomique (Genom\u2019IC) , Paris 75014 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"Lombard","sequence":"additional","affiliation":[{"name":"CNRS UMR8104, INSERM U1016, Institut Cochin, Universit\u00e9 Paris Cit\u00e9 , Paris 75014 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Perlemoine","sequence":"additional","affiliation":[{"name":"CNRS UMR8104, INSERM U1016, Institut Cochin, Universit\u00e9 Paris Cit\u00e9 , Paris 75014 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6628-8807","authenticated-orcid":false,"given":"Fid\u00e9line","family":"Bonnet-Serrano","sequence":"additional","affiliation":[{"name":"CNRS UMR8104, INSERM U1016, Institut Cochin, Universit\u00e9 Paris Cit\u00e9 , Paris 75014 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Jouinot","sequence":"additional","affiliation":[{"name":"CNRS UMR8104, INSERM U1016, Institut Cochin, Universit\u00e9 Paris Cit\u00e9 , Paris 75014 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7458-7102","authenticated-orcid":false,"given":"Mirella","family":"Hage","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Nutrition, H\u00f4pital Ambroise Par\u00e9, Assistance Publique-H\u00f4pitaux de Paris , Boulogne-Billancourt 92100 ,","place":["France"]},{"name":"UFR des Sciences de la Sant\u00e9 Simone Veil, Universit\u00e9 de Versailles Saint-Quentin-en-Yvelines , Montigny-le-Bretonneux 78180 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Raffin-Sanson","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Nutrition, H\u00f4pital Ambroise Par\u00e9, Assistance Publique-H\u00f4pitaux de Paris , Boulogne-Billancourt 92100 ,","place":["France"]},{"name":"UFR des Sciences de la Sant\u00e9 Simone Veil, Universit\u00e9 de Versailles Saint-Quentin-en-Yvelines , Montigny-le-Bretonneux 78180 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Letourneur","sequence":"additional","affiliation":[{"name":"CNRS UMR8104, INSERM U1016, Institut Cochin, Universit\u00e9 Paris Cit\u00e9 , Paris 75014 ,","place":["France"]},{"name":"INSERM U1016, Institut Cochin, Plate-Forme S\u00e9quen\u00e7age et G\u00e9nomique (Genom\u2019IC) , Paris 75014 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Emile","sequence":"additional","affiliation":[{"name":"Department of Pathology, H\u00f4pital Ambroise Par\u00e9, Assistance Publique\u2013H\u00f4pitaux de Paris , Boulogne-Billancourt 92100 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2551-3008","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Bertherat","sequence":"additional","affiliation":[{"name":"CNRS UMR8104, INSERM U1016, Institut Cochin, Universit\u00e9 Paris Cit\u00e9 , Paris 75014 ,","place":["France"]},{"name":"Department of Endocrinology, H\u00f4pital Cochin, Reference and Competence Center for Rare Adrenal Diseases and Rare Pituitary Diseases, Assistance Publique\u2013H\u00f4pitaux de Paris , Paris 75014 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Villa","sequence":"additional","affiliation":[{"name":"CNRS UMR8104, INSERM U1016, Institut Cochin, Universit\u00e9 Paris Cit\u00e9 , Paris 75014 ,","place":["France"]},{"name":"Department of Pathology, H\u00f4pital Lariboisi\u00e8re, Assistance Publique\u2013H\u00f4pitaux de Paris , Paris 75010 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0735-8278","authenticated-orcid":false,"given":"Bertrand","family":"Baussart","sequence":"additional","affiliation":[{"name":"CNRS UMR8104, INSERM U1016, Institut Cochin, Universit\u00e9 Paris Cit\u00e9 , Paris 75014 ,","place":["France"]},{"name":"Department of Neurosurgery, H\u00f4pital Lariboisi\u00e8re, Assistance Publique\u2013H\u00f4pitaux de Paris , Paris 75010 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Assi\u00e9","sequence":"additional","affiliation":[{"name":"CNRS UMR8104, INSERM U1016, Institut Cochin, Universit\u00e9 Paris Cit\u00e9 , Paris 75014 ,","place":["France"]},{"name":"Department of Endocrinology, H\u00f4pital Cochin, Reference and Competence Center for Rare Adrenal Diseases and Rare Pituitary Diseases, Assistance Publique\u2013H\u00f4pitaux de Paris , Paris 75014 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"issue":"5","key":"2025111719113575600_lvaf196-B1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and treatment of pituitary adenomas: a review","volume":"317","author":"Molitch","year":"2017","journal-title":"JAMA"},{"issue":"6","key":"2025111719113575600_lvaf196-B2","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1210\/endrev\/bnac010","article-title":"Clinical biology of the pituitary adenoma","volume":"43","author":"Melmed","year":"2022","journal-title":"Endocr Rev"},{"issue":"5","key":"2025111719113575600_lvaf196-B3","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1530\/EJE-09-0012","article-title":"Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients","volume":"160","author":"Delgrange","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2025111719113575600_lvaf196-B4","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1530\/EJE-12-0236","article-title":"Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients","volume":"167","author":"Vroonen","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025111719113575600_lvaf196-B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12902-020-0543-4","article-title":"Predictors of dopamine agonist resistance in prolactinoma patients","volume":"20","author":"Vermeulen","year":"2020","journal-title":"BMC Endocr Disord"},{"issue":"3","key":"2025111719113575600_lvaf196-B6","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1210\/jc.2014-3670","article-title":"Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients","volume":"100","author":"Salenave","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025111719113575600_lvaf196-B7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/BF03343583","article-title":"Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide","volume":"22","author":"Suliman","year":"1999","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"2025111719113575600_lvaf196-B8","doi-asserted-by":"publisher","first-page":"6290","DOI":"10.1210\/jc.2005-0998","article-title":"The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly","volume":"90","author":"Bhayana","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025111719113575600_lvaf196-B9","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1210\/clinem\/dgab125","article-title":"Machine learning-based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands","volume":"106","author":"Wildemberg","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025111719113575600_lvaf196-B10","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1210\/CLINEM\/DGAA387","article-title":"Multivariable prediction model for biochemical response to first-generation somatostatin receptor ligands in acromegaly","volume":"105","author":"Coopmans","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025111719113575600_lvaf196-B11","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1210\/JC.2010-0573","article-title":"Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure","volume":"95","author":"Puig-Domingo","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025111719113575600_lvaf196-B12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1365-2265.2011.04286.x","article-title":"Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly","volume":"77","author":"Heck","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"2025111719113575600_lvaf196-B13","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1530\/ERC-16-0356","article-title":"T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly","volume":"23","author":"Potorac","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"2025111719113575600_lvaf196-B14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1530\/EJE-18-0254","article-title":"MRI T2 signal intensity and tumor response in patients with GH-secreting pituitary macroadenoma: PRIMARYS post hoc analysis","volume":"180","author":"Bonneville","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025111719113575600_lvaf196-B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm12010025","article-title":"Resistance to somatostatin analogs in Italian acromegaly patients: the MISS study","volume":"12","author":"Berton","year":"2023","journal-title":"J Clin Med"},{"issue":"1","key":"2025111719113575600_lvaf196-B16","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1365-2265.2011.04163.x","article-title":"Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly","volume":"76","author":"Fougner","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2025111719113575600_lvaf196-B17","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/S11102-012-0445-1","article-title":"Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience","volume":"16","author":"Brzana","year":"2013","journal-title":"Pituitary"},{"issue":"11","key":"2025111719113575600_lvaf196-B18","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1210\/clinem\/dgac512","article-title":"Predictive factors of somatostatin receptor ligand response in acromegaly\u2014a prospective study","volume":"107","author":"Ilie","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025111719113575600_lvaf196-B19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1530\/EJE-22-0339","article-title":"Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation study","volume":"187","author":"Campana","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025111719113575600_lvaf196-B20","doi-asserted-by":"publisher","first-page":"K6","DOI":"10.1093\/ejendo\/lvae170","article-title":"The value of digital quantification of somatostatin receptor subtypes 2 and 5 immunostaining in GH-secreting pituitary tumors","volume":"192","author":"Campana","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025111719113575600_lvaf196-B21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ccell.2019.11.002","article-title":"Pangenomic classification of pituitary neuroendocrine tumors","volume":"37","author":"Neou","year":"2020","journal-title":"Cancer Cell"},{"issue":"8","key":"2025111719113575600_lvaf196-B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/neuonc\/noac053","article-title":"TRIM65 determines the fate of a novel subtype of pituitary neuroendocrine tumors via ubiquitination and degradation of TPIT","volume":"24","author":"Yao","year":"2022","journal-title":"Neuro Oncol"},{"issue":"1","key":"2025111719113575600_lvaf196-B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-024-01325-4","article-title":"Single-cell transcriptomics reveal distinct immune-infiltrating phenotypes and macrophage\u2013tumor interaction axes among different lineages of pituitary neuroendocrine tumors","volume":"16","author":"Lin","year":"2024","journal-title":"Genome Med"},{"issue":"1","key":"2025111719113575600_lvaf196-B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-023-01267-3","article-title":"Single-cell transcriptomic analysis reveals tumor cell heterogeneity and immune microenvironment features of pituitary neuroendocrine tumors","volume":"16","author":"Yan","year":"2024","journal-title":"Genome Med"},{"issue":"23","key":"2025111719113575600_lvaf196-B25","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.3390\/cells11233846","article-title":"Transcriptomic classification of pituitary neuroendocrine tumors causing acromegaly","volume":"11","author":"Rymuza","year":"2022","journal-title":"Cells"},{"issue":"1","key":"2025111719113575600_lvaf196-B26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000533692","article-title":"DNA methylation pattern in somatotroph pituitary neuroendocrine tumors","volume":"114","author":"Kober","year":"2024","journal-title":"Neuroendocrinology"},{"issue":"1","key":"2025111719113575600_lvaf196-B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-024-02686-1","article-title":"Pituitary neuroendocrine tumors with PIT1\/SF1 co-expression show distinct clinicopathological and molecular features","volume":"147","author":"Dottermusch","year":"2024","journal-title":"Acta Neuropathol"},{"issue":"2","key":"2025111719113575600_lvaf196-B28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000156116","article-title":"Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists","volume":"89","author":"Passos","year":"2009","journal-title":"Neuroendocrinology"},{"issue":"3","key":"2025111719113575600_lvaf196-B29","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1530\/EJE-11-0656","article-title":"Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels","volume":"166","author":"Shimazu","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2025111719113575600_lvaf196-B30","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1210\/jc.85.2.781","article-title":"Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes","volume":"85","author":"Jaquet","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025111719113575600_lvaf196-B31","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11102-009-0175-1","article-title":"Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment","volume":"12","author":"Casarini","year":"2009","journal-title":"Pituitary"},{"key":"2025111719113575600_lvaf196-B32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.mce.2015.09.016","article-title":"Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors","volume":"417","author":"Kiseljak-Vassiliades","year":"2015","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"2025111719113575600_lvaf196-B33","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1530\/EJE-15-0391","article-title":"Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly","volume":"174","author":"Gatto","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2025111719113575600_lvaf196-B34","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025111719113575600_lvaf196-B35","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025111719113575600_lvaf196-B36","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1210\/jc.2010-1048","article-title":"Pituitary incidentaloma: an endocrine society clinical practice guideline","volume":"96","author":"Freda","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025111719113575600_lvaf196-B37","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1530\/EJE-21-0293","article-title":"Pituitary surgery as alternative to dopamine agonists treatment for microprolactinomas: a cohort study","volume":"185","author":"Baussart","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"2025111719113575600_lvaf196-B38","volume-title":"WHO Classification of Tumours","author":"Central Nervous System Tumours","year":"2021","edition":"5th"},{"key":"2025111719113575600_lvaf196-B39","volume-title":"WHO Classification of Tumours","author":"Endocrine and Neuroendocrine Tumours","year":"2022","edition":"5th"},{"issue":"6","key":"2025111719113575600_lvaf196-B40","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00428-019-02655-0","article-title":"A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal","volume":"475","author":"Villa","year":"2019","journal-title":"Virchows Arch"},{"issue":"1","key":"2025111719113575600_lvaf196-B41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"issue":"9","key":"2025111719113575600_lvaf196-B42","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/nbt.2931","article-title":"Normalization of RNA-seq data using factor analysis of control genes or samples","volume":"32","author":"Risso","year":"2014","journal-title":"Nat Biotechnol"},{"issue":"10","key":"2025111719113575600_lvaf196-B43","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.tig.2013.05.010","article-title":"Human housekeeping genes, revisited","volume":"29","author":"Eisenberg","year":"2013","journal-title":"Trends Genet"},{"issue":"1","key":"2025111719113575600_lvaf196-B44","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/1471-2105-11-367","article-title":"A flexible R package for nonnegative matrix factorization","volume":"11","author":"Gaujoux","year":"2010","journal-title":"BMC Bioinformatics"},{"key":"2025111719113575600_lvaf196-B45","author":"Kolde"},{"issue":"1","key":"2025111719113575600_lvaf196-B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v025.i01","article-title":"FactoMineR: an R package for multivariate analysis","volume":"25","author":"L\u00ea","year":"2008","journal-title":"J Stat Softw"},{"issue":"7","key":"2025111719113575600_lvaf196-B47","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-Sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"43","key":"2025111719113575600_lvaf196-B48","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2025111719113575600_lvaf196-B49","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"Newman","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"6","key":"2025111719113575600_lvaf196-B50","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1530\/EJE-14-0990","article-title":"Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth","volume":"172","author":"Delgrange","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2025111719113575600_lvaf196-B51","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00401-020-02180-4","article-title":"The KBTBD6\/7-DRD2 axis regulates pituitary adenoma sensitivity to dopamine agonist treatment","volume":"140","author":"Liu","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"1","key":"2025111719113575600_lvaf196-B52","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1038\/s41467-020-16052-8","article-title":"Somatic SF3B1 hotspot mutation in prolactinomas","volume":"11","author":"Li","year":"2020","journal-title":"Nat Commun"},{"issue":"3","key":"2025111719113575600_lvaf196-B53","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1093\/ejendo\/lvad114","article-title":"Prevalence and clinical correlations of SF3B1 variants in lactotroph tumours","volume":"189","author":"Simon","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"35","key":"2025111719113575600_lvaf196-B54","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1038\/s41388-018-0304-2","article-title":"E-cadherin in contact inhibition and cancer","volume":"37","author":"Mendonsa","year":"2018","journal-title":"Oncogene"},{"issue":"9","key":"2025111719113575600_lvaf196-B55","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41574-021-00514-0","article-title":"Drug resistance in pituitary tumours: from cell membrane to intracellular signalling","volume":"17","author":"Peverelli","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"2025111719113575600_lvaf196-B56","doi-asserted-by":"publisher","first-page":"4715","DOI":"10.1210\/en.2013-1672","article-title":"\u03b2-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly","volume":"154","author":"Gatto","year":"2013","journal-title":"Endocrinology"},{"issue":"9","key":"2025111719113575600_lvaf196-B57","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1002\/ijc.24602","article-title":"Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly","volume":"125","author":"Theodoropoulou","year":"2009","journal-title":"Int J Cancer"},{"issue":"3","key":"2025111719113575600_lvaf196-B58","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1530\/ERC-12-0020","article-title":"AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression","volume":"19","author":"Kasuki","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"2025111719113575600_lvaf196-B59","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"19","key":"2025111719113575600_lvaf196-B60","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1101\/gad.8.19.2302","article-title":"The nuclear receptor steroidogenic factor 1 acts at multiple levels of the reproductive axis","volume":"8","author":"Ingraham","year":"1994","journal-title":"Genes Dev"},{"issue":"5","key":"2025111719113575600_lvaf196-B61","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S0092-8674(00)80770-9","article-title":"Reciprocal interactions of Pit1 and GATA2 mediate signaling gradient- induced determination of pituitary cell types","volume":"97","author":"Dasen","year":"1999","journal-title":"Cell"},{"issue":"1","key":"2025111719113575600_lvaf196-B62","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/modpathol.3880484","article-title":"Expression of GATA-2 in human pituitary adenomas","volume":"15","author":"Umeoka","year":"2002","journal-title":"Mod Pathol"},{"issue":"4","key":"2025111719113575600_lvaf196-B63","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/s41379-018-0167-7","article-title":"GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors","volume":"32","author":"Mete","year":"2019","journal-title":"Mod Pathol"},{"issue":"4","key":"2025111719113575600_lvaf196-B64","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11102-008-0162-y","article-title":"Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma","volume":"14","author":"Fusco","year":"2011","journal-title":"Pituitary"},{"issue":"2","key":"2025111719113575600_lvaf196-B65","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s12020-018-1638-9","article-title":"Treatment of multiresistant prolactinomas with a combination of cabergoline and octreotide LAR","volume":"61","author":"Sosa-Eroza","year":"2018","journal-title":"Endocrine"},{"issue":"5701","key":"2025111719113575600_lvaf196-B66","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/278252a0","article-title":"Dopamine inhibits adenylate cyclase in human prolactin-secreting pituitary adenomas","volume":"278","author":"De Camilli","year":"1979","journal-title":"Nature"},{"issue":"4","key":"2025111719113575600_lvaf196-B67","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1016\/S0021-9258(19)39945-4","article-title":"Coupling of a cloned rat dopamine-D2 receptor to inhibition of adenylyl cyclase and prolactin secretion","volume":"265","author":"Albert","year":"1990","journal-title":"J Biol Chem"},{"issue":"2","key":"2025111719113575600_lvaf196-B68","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1210\/endrev\/bnac024","article-title":"Biological and therapeutic implications of the tumor microenvironment in pituitary adenomas","volume":"44","author":"Ilie","year":"2023","journal-title":"Endocr Rev"},{"issue":"7","key":"2025111719113575600_lvaf196-B69","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1210\/JCEM.82.7.4088","article-title":"Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study","volume":"82","author":"Delgrange","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025111719113575600_lvaf196-B70","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1530\/eje.1.02339","article-title":"What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics","volume":"156","author":"G\u00fcrlek","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025111719113575600_lvaf196-B71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-19012-4","article-title":"Single-cell transcriptomics identifies divergent developmental lineage trajectories during human pituitary development","volume":"11","author":"Zhang","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"2025111719113575600_lvaf196-B72","doi-asserted-by":"publisher","first-page":"E66","DOI":"10.1210\/jc.2012-2609","article-title":"Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly","volume":"98","author":"Gatto","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025111719113575600_lvaf196-B73","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3275\/8305","article-title":"Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs","volume":"36","author":"Wildemberg","year":"2013","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"2025111719113575600_lvaf196-B74","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1210\/jc.2008-0126","article-title":"Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas","volume":"93","author":"Fusco","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025111719113575600_lvaf196-B75","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1530\/ERC-18-0565","article-title":"Molecular profiling for acromegaly treatment: a validation study","volume":"27","author":"Puig-Domingo","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"2025111719113575600_lvaf196-B76","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1210\/jc.2009-2197","article-title":"The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response","volume":"95","author":"Fougner","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025111719113575600_lvaf196-B77","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1111\/jcmm.13851","article-title":"E-cadherin expression is associated with somatostatin analogue response in acromegaly","volume":"23","author":"Venegas-Moreno","year":"2019","journal-title":"J Cell Mol Med"},{"issue":"March","key":"2025111719113575600_lvaf196-B78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2021.646210","article-title":"Epithelial\u2013mesenchymal transition in the resistance to somatostatin receptor ligands in acromegaly","volume":"12","author":"Gil","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2025111719113575600_lvaf196-B79","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/1755-0998.12529","article-title":"Evaluation of TagSeq, a reliable low-cost alternative for RNAseq","volume":"16","author":"Lohman","year":"2016","journal-title":"Mol Ecol Resour"},{"issue":"1","key":"2025111719113575600_lvaf196-B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-019-1671-x","article-title":"Transcriptomics enabled by bulk RNA barcoding and sequencing","volume":"20","author":"Alpern","year":"2019","journal-title":"Genome Biol"},{"issue":"1","key":"2025111719113575600_lvaf196-B81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12864-020-6478-3","article-title":"3\u2032Pool-seq: an optimized cost-efficient and scalable method of whole-transcriptome gene expression profiling","volume":"21","author":"Sholder","year":"2020","journal-title":"BMC Genomics"},{"issue":"6","key":"2025111719113575600_lvaf196-B82","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1210\/jcem-71-6-1416","article-title":"Clinical characteristics of acromegalic patients whose pituitary tumors contain mutant Gs protein","volume":"71","author":"Landis","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025111719113575600_lvaf196-B83","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11102-007-0058-2","article-title":"Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission","volume":"10","author":"Freda","year":"2007","journal-title":"Pituitary"},{"issue":"23","key":"2025111719113575600_lvaf196-B84","doi-asserted-by":"publisher","first-page":"5685","DOI":"10.3390\/cancers15235685","article-title":"Hotspots of somatic genetic variation in pituitary neuroendocrine tumors","volume":"15","author":"Torres-Mor\u00e1n","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/4\/474\/64952463\/lvaf196.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/4\/474\/64952463\/lvaf196.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:11:43Z","timestamp":1763424703000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/193\/4\/474\/8303484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvaf196","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,30]]}}}